Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

Gene Therapy
S S AndreanskyR J Whitley

Abstract

This report describes a test of the hypothesis that the oncolytic effect of genetically engineered, replication competent herpes simplex viruses (HSV) depends both on cell destruction by the virus and an immune response to the tumor cells induced in an immunocompetent animal system. The oncolytic vector was a HSV recombinant virus in which both copies of the gamma 1 34.5 gene were replaced with the murine genes encoding the cytokine interleukin-4 (IL-4) or interleukin-10 (IL-10). The hypothesis predicted that if an immune response plays a role in survival following intratumoral treatment of tumor-bearing animals with HSV, expression of IL-4 should prolong survival whereas expression of IL-10 should reduce it. The results are that (1) these cytokines can be expressed by HSV in productively infected cells both in vitro and in vivo; (2) HSV-expressing IL-4 or IL-10 genes were able to infect and destroy glioma cells in vitro; (3) intracerebral inoculation of HSV expressing either IL-4 or IL-10 into syngeneic murine glioma GL-261 cells implanted in the brains of immunocompetent C57BL/6 mice produced dramatically opposite physiologic responses. The IL-4 HSV significantly prolonged survival of tumor bearers, whereas tumor-bearing mice...Continue Reading

Citations

Feb 2, 2000·Reviews in Medical Virology·J M MarkertR J Whitley
Apr 25, 2006·Journal of Biomedical Science·Lih-Hwa Hwang
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jacqueline Nuss ParkerJames M Markert
Dec 10, 1999·The Annals of Thoracic Surgery·E S LambrightL R Kaiser
May 18, 2000·Journal of Neuroimmunology·Y KitamuraP J Gebicke-Haerter
Mar 4, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·R L GutmanD R Lu
Nov 26, 1999·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·P E OyvindM Lund-Johansen
May 23, 2001·Critical Reviews in Oncology/hematology·E GalanisS J Russell
May 26, 2009·Chemical Reviews·Christopher Alvarez-BreckenridgeE Antonio Chiocca
Oct 19, 2005·Gene Therapy·R ArgnaniR Manservigi
Dec 14, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Balveen Kaur, E Antonio Chiocca
Jun 5, 2003·Current Opinion in Oncology·Carlo MarrasFrancesco DiMeco
Mar 2, 2012·Journal of Virology·James M MarkertRichard J Whitley
Jan 29, 2013·Molekuliarnaia biologiia·N V GubanovaP M Chumakov
Jul 18, 2002·The Journal of Clinical Investigation·Richard J Whitley, Bernard Roizman
Apr 5, 2000·The Journal of Clinical Investigation·R L Martuza
Jul 4, 2003·Annals of Surgical Oncology·John T Mullen, Kenneth K Tanabe
Jul 5, 2006·Neurosurgical Focus·R P GlickE P Cohen
Jul 31, 2007·Future Microbiology·Balveen Kaur, E Antonio Chiocca
May 21, 2013·CNS Oncology·Ryuichi Kanai, Samuel D Rabkin
Feb 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·J N ParkerJ M Markert

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cells: Gene Expression

B lymphocytes are white blood cells that play a role in the adaptive immune system by secreting antibodies. Here is the latest research on gene expression in B cells.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.